A Phase 1/2 interventional study of IVA and TEZ/IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 38 sites in 4 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-18.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 8th largest by enrollment, is one of 3 that started in 2017, is one of 2 in phase 1/2, and was the 15th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 25 · Phase 4 3
First in 2012; this study’s year is marked. 3 started in 2017.
This study's enrollment of 225 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 100 across the 43 interventional studies. Of the 36 that completed or were terminated, 31 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 5 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 21st largest by enrollment of the 116 interventional ones that give a count, is one of 7 that started in 2017, is one of 3 in phase 1/2, and was the 66th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing tezacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This is a first-in-human and proof-of-concept study of VX-445. The study includes 6 parts. Parts A, B, and C were conducted in healthy subjects. Parts D, E, and F were conducted in subjects with Cystic Fibrosis (CF) who are homozygous for the F508del mutation of the CF transmembrane conductance regulator (CFTR) gene (F/F genotype), or who are heterozygous for the F508del mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ, IVA, or TEZ/IVA (F/MF genotypes).
Key Inclusion Criteria:
Parts A, B, and C:
Parts D, E, and F:
Subjects must have an eligible CFTR genotype:
Key Exclusion Criteria:
Parts A, B, and C:
Parts D, E, and F:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants without CF who received single dose of placebo matched to VX-445 in Cohort A1 to A5.
Drug: Matched Placebo
Participants without CF who received single ascending dose of VX-445 tablet starting from 20 milligrams (mg) to 360 mg in Cohort A1 to A5.
Drug: VX-445
Participants without CF who received single dose of VX-445 100 mg tablet on Day 1 in fasted state and on Day 7 in fed state, followed by VX-445 20 mg intravenous (IV) injection on Day 13 in fed state in Cohort A7.
Drug: VX-445
Participants without CF who received multiple doses of placebo matched to VX-445 once daily (qd) for 10 days in Cohort B1 to B4.
Drug: Matched Placebo
Participants without CF who received VX-445 tablet qd for 10 days in Cohort B1 (60 mg), B2 (120 mg), B3 (240 mg) and B4 (340 mg).
Drug: VX-445
Participants without CF who received placebo matched to VX-445/TEZ/IVA triple combination (TC) qd in the morning and placebo matched to IVA in the evening for 14 days.
Drug: Matched Placebo
Participants without CF who received VX-445 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in Cohort C1; VX-445 280 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in Cohort C2 and VX-445 100 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in Cohort C3 for 14 days.
Drug: IVA · Drug: TEZ/IVA · Drug: VX-445
Participants with CF, F/MF genotype who received placebo matched to VX-445/TEZ/IVA TC qd in the morning and placebo matched to IVA qd in the evening for 4 weeks in the TC treatment period.
Drug: Matched Placebo
Participants with CF, F/MF genotype who received VX-445 50 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the TC treatment period.
Drug: IVA · Drug: TEZ/IVA · Drug: VX-445
Participants with CF, F/MF genotype who received VX-445 100 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the TC treatment period.
Drug: IVA · Drug: TEZ/IVA · Drug: VX-445
Participants with CF, F/MF genotype who received VX-445 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the TC treatment period.
Drug: IVA · Drug: TEZ/IVA · Drug: VX-445
Following run-in period of 4 weeks with TEZ/IVA, participants with CF, F/F genotype who received TEZ 100 mg qd/IVA 150 mg q12h and placebo matched to VX-445 for 4 weeks in the TC treatment period.
Drug: TEZ/IVA
Following run-in period of 4 weeks with TEZ/IVA, participants with CF, F/F genotype who received VX-445 200 mg qd/TEZ 100 mg qd /IVA 150 mg q12h for 4 weeks in the TC treatment period.
Drug: IVA · Drug: TEZ/IVA · Drug: VX-445
Participants with CF, F/MF genotype who received placebo matched to VX-445/TEZ/VX-561 for 4 weeks in the TC treatment period.
Drug: Matched Placebo
Participants with CF, F/MF genotype who received VX-445 200 mg qd/TEZ 100 mg qd/VX-561 150 mg qd for 4 weeks in the TC treatment period.
Drug: VX-445 · Drug: TEZ · Drug: VX-561
IVA tablet for oral administration
Also known as: VX-770, ivacaftor
Drug pages: Tezacaftor · Ivacaftor
TEZ/IVA fixed-dose combination for oral administration.
Also known as: VX-661/VX-770, tezacaftor/ivacaftor
VX-445 tablet for oral administration.
Also known as: ELX, elexacaftor
Matched placebo.
Tablet for oral administration.
Also known as: VX-661, tezacaftor
Tablet for oral administration.
Also known as: CTP-656
VX-445 IV injection
Also known as: ELX, elexacaftor
Parts A, B and C: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From first dose of study drug in treatment period up to safety follow-up (up to 28 days)
Parts D, E and F: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From first dose of study drug in TC treatment period up to 28 days after last dose of study drug (up to 5 weeks)
Part D: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline through Day 29
Part E: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline through Day 29
Part F: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline through Day 29
Part A: Maximum Observed Concentration (Cmax) of VX-445
Time frame: Cohort A1-A5: Pre-dose to 96 hours post-dose; Cohort A7: Pre-dose to 120 hours post-dose
Part A: Area Under Plasma Concentration Time Curve From Time of Dosing to Last Measurable Concentration (AUC0-tlast) of VX-445
Time frame: Cohort A1-5: Pre-dose to 96 hours post-dose; Cohort A7: Pre-dose to 120 hours post-dose
Part B: Maximum Observed Concentration (Cmax) of VX-445
Time frame: Pre-dose to 96 hours post-dose on Day 1 and Day 10
Part B: Area Under Plasma Concentration Time Curve From Time of Dosing to Last Measurable Concentration (AUC0-tlast) of VX-445
Time frame: Pre-dose to 96 hours post-dose on Day 1 and Day 10
Part B: Observed Pre-dose Plasma Concentration (Ctrough) of VX-445
Time frame: Pre-dose on Day 10
Part C: Maximum Observed Concentration (Cmax) of VX-445, TEZ and Its Metabolites (M1-TEZ and M2-TEZ)
Time frame: Pre-dose to 96 hours post-dose on Day 1, Day 7 and Day 14
Part C: Area Under Plasma Concentration Time Curve From Time of Dosing to Last Measurable Concentration (AUC0-tlast) of VX-445, TEZ and Its Metabolites (M1-TEZ and M2-TEZ)
Time frame: Pre-dose to 96 hours post-dose on Day 1, Day 7 and Day 14
Part C: Maximum Observed Concentration (Cmax) of IVA and Its Metabolites (M1-IVA and M6-IVA)
Time frame: Pre-dose to 96 hours post-dose on Day 1, Day 7 and Day 14
Part C: Area Under Plasma Concentration Time Curve From Time of Dosing to Last Measurable Concentration (AUC0-tlast) of IVA and Its Metabolites (M1-IVA and M6-IVA)
Time frame: Pre-dose to 96 hours post-dose on Day 1, Day 7 and Day 14
Part C: Observed Pre-dose Concentration (Ctrough) of VX-445, TEZ and Its Metabolites (M1-TEZ and M2-TEZ)
Time frame: Pre-dose on Day 7 and Day 14
Part C: Observed Pre-dose Concentration (Ctrough) of IVA and Its Metabolites (M1-IVA and M6-IVA)
Time frame: Pre-dose on Day 7 and Day 14
Part D: Observed Pre-dose Plasma Concentration (Ctrough) of VX-445, TEZ and Its Metabolite (M1-TEZ), IVA and Its Metabolite (M1-IVA)
Time frame: Pre-dose on Day 15 and Day 29
Part E: Observed Pre-dose Concentration (Ctrough) of VX-445, TEZ and Its Metabolite (M1-TEZ) and IVA and Its Metabolite (M1-IVA)
Time frame: Pre-dose on Day 15 and Day 29
Part F: Observed Pre-dose Concentration (Ctrough) of VX-445, TEZ and Its Metabolite (M1-TEZ) and VX-561
Time frame: Pre-dose on Day 15 and Day 29
Part D: Absolute Change in Sweat Chloride Concentration
Sweat samples were collected using an approved collection device.
Time frame: From Baseline through Day 29
Part E: Absolute Change in Sweat Chloride Concentration
Sweat samples were collected using an approved collection device.
Time frame: From Baseline through Day 29
Part F: Absolute Change in Sweat Chloride Concentration
Sweat samples were collected using an approved collection device.
Time frame: From Baseline through Day 29
Part D: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline through Day 29
Part E: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline through Day 29
Part F: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline through Day 29
Part D: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: From Baseline through Day 29
Part E: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: From Baseline through Day 29
Part F: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: From Baseline through Day 29
| Milestone | Part A: Pooled Placebo (Except Cohort A7) | Part A: VX-445 (Except Cohort A7) | Part A: VX-445 (Cohort A7) | Part B: Pooled Placebo (Cohort B1 to B4) | Part B: VX-445 (Cohort B1 to B4) | Part C: Pooled Placebo (Cohort C1 to C3) | Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3) | Part D: Placebo | Part D: VX-445/TEZ/IVA TC - Low Dose | Part D: VX-445/TEZ/IVA TC - Medium Dose | Part D: VX-445/TEZ/IVA TC - High Dose | Part E: TEZ/IVA | Part E: VX-445/TEZ/IVA TC | Part F: Placebo | Part F: VX-445/TEZ/VX-561 TC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 9 | 30 | 8 | 7 | 25 | 6 | 17 | 12 | 10 | 22 | 21 | 7 | 21 | 8 | 22 |
| Safety set | 9 | 30 | 8 | 7 | 25 | 6 | 17 | 12 | 10 | 22 | 21 | 7 | 21 | 8 | 21 |
| Completed | 9 | 30 | 8 | 7 | 24 | 6 | 17 | 12 | 10 | 22 | 21 | 7 | 20 | 8 | 21 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Randomized, never dosed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Participants | Part A: Pooled Placebo (Except Cohort A7) | Part A: VX-445 (Except Cohort A7) | Part A: VX-445 (Cohort A7) | Part B: Pooled Placebo (Cohort B1 to B4) | Part B: VX-445 (Cohort B1 to B4) | Part C: Pooled Placebo (Cohort C1 to C3) | Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3) |
|---|---|---|---|---|---|---|---|
| Participants with AEs | 0 | 3 | 1 | 2 | 2 | 2 | 5 |
| Participants with SAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants | Part D: Placebo | Part D: VX-445/TEZ/IVA TC | Part E: TEZ/IVA | Part E: VX-445/TEZ/IVA TC | Part F: Placebo | Part F: VX-445/TEZ/VX-561 TC |
|---|---|---|---|---|---|---|
| Participants with AEs | 12 | 49 | 5 | 19 | 7 | 19 |
| Participants with SAEs | 2 | 3 | 1 | 0 | 1 | 0 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percentage points | Part D: Placebo | Part D: VX-445/TEZ/IVA TC - Low Dose | Part D: VX-445/TEZ/IVA TC - Medium Dose | Part D: VX-445/TEZ/IVA TC - High Dose |
|---|---|---|---|---|
| Part D: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) | 0.0 ± 2.0 | 11.1 ± 2.1 | 7.9 ± 1.4 | 13.8 ± 1.4 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percentage points | Part E: TEZ/IVA | Part E: VX-445/TEZ/IVA TC |
|---|---|---|
| Part E: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) | 0.4 ± 2.8 | 11.0 ± 1.5 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percentage points | Part F: Placebo | Part F: VX-445/TEZ/VX-561 TC |
|---|---|---|
| Part F: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) | 1.2 ± 2.6 | 11.7 ± 1.6 |
| microgram per milliliter | Part A: VX-445 (Cohort A1) | Part A: VX-445 (Cohort A2) | Part A: VX-445 (Cohort A3) | Part A: VX-445 (Cohort A4) | Part A: VX-445 (Cohort A5) | Part A: VX-445 (Cohort A7-Fasted) | Part A: VX-445 (Cohort A7-Fed) | Part A: VX-445 (Cohort A7-IV) |
|---|---|---|---|---|---|---|---|---|
| Part A: Maximum Observed Concentration (Cmax) of VX-445 | 0.398 ± 23.0 | 0.989 ± 35.1 | 2.52 ± 13.0 | 4.56 ± 28.2 | 7.07 ± 19.1 | 0.486 ± 27.4 | 1.76 ± 14.6 | 0.740 ± 27.1 |
| microgram*hour per milliliter | Part A: VX-445 (Cohort A1) | Part A: VX-445 (Cohort A2) | Part A: VX-445 (Cohort A3) | Part A: VX-445 (Cohort A4) | Part A: VX-445 (Cohort A5) | Part A: VX-445 (Cohort A7-Fasted) | Part A: VX-445 (Cohort A7-Fed) | Part A: VX-445 (Cohort A7-IV) |
|---|---|---|---|---|---|---|---|---|
| Part A: Area Under Plasma Concentration Time Curve From Time of Dosing to Last Measurable Concentration (AUC0-tlast) of VX-445 | 11.4 ± 34.2 | 30.8 ± 21.2 | 87.1 ± 39.9 | 125 ± 34.2 | 286 ± 9.30 | 21.8 ± 31.5 | 55.1 ± 14.9 | 13.6 ± 19.7 |
| microgram per milliliter | Part B: VX-445 (Cohort B1) | Part B: VX-445 (Cohort B2) | Part B: VX-445 (Cohort B3) | Part B: VX-445 (Cohort B4) |
|---|---|---|---|---|
| Day 1 | 1.18 ± 19.9 | 2.82 ± 25.5 | 3.47 ± 52.9 | 9.56 ± 65.6 |
| Day 10 | 2.13 ± 15 | 5.83 ± 28.1 | 11.4 ± 27.2 | 18.2 ± 29.5 |
| microgram*hour per milliliter | Part B: VX-445 (Cohort B1) | Part B: VX-445 (Cohort B2) | Part B: VX-445 (Cohort B3) | Part B: VX-445 (Cohort B4) |
|---|---|---|---|---|
| Day 1 | 17.9 ± 20.0 | 42.2 ± 19.5 | 57.9 ± 42.8 | 119 ± 27.5 |
| Day 10 | 61.4 ± 21.8 | 183 ± 32.7 | 452 ± 41.5 | 692 ± 47.6 |
| microgram per milliliter | Part B: VX-445 (Cohort B1) | Part B: VX-445 (Cohort B2) | Part B: VX-445 (Cohort B3) | Part B: VX-445 (Cohort B4) |
|---|---|---|---|---|
| Part B: Observed Pre-dose Plasma Concentration (Ctrough) of VX-445 | 1.05 ± 24.5 | 2.81 ± 33.2 | 7.10 ± 30.1 | 11.5 ± 32.0 |
| microgram per milliliter | Part C: VX-445/TEZ/IVA TC (Cohort C1) | Part C: VX-445/TEZ/IVA TC (Cohort C2) | Part C: VX-445/TEZ/IVA TC (Cohort C3) |
|---|---|---|---|
| VX-445: Day 1 | 3.04 ± 23.2 | 4.86 ± 25.4 | 1.72 ± 16.5 |
| VX-445: Day 7 | 8.29 ± 31.9 | 10.3 ± 18.4 | 3.58 ± 14.8 |
| VX-445: Day 14 | 8.71 ± 9.65 | 14.0 ± 19.2 | 4.73 ± 15.9 |
| TEZ: Day 1 | 3.81 ± 16.4 | 5.67 ± 17.2 | 5.38 ± 19.2 |
| TEZ: Day 7 | 7.09 ± 19.4 | 8.29 ± 13.6 | 7.01 ± 14.7 |
| TEZ: Day 14 | 8.11 ± 21.2 | 9.07 ± 7.60 | 8.60 ± 12.8 |
| M1-TEZ: Day 1 | 0.929 ± 35 | 0.988 ± 31.7 | 1.30 ± 17.3 |
| M1-TEZ: Day 7 | 4.34 ± 28.7 | 5.19 ± 16.8 | 5.86 ± 11.3 |
| M1-TEZ: Day 14 | 5.77 ± 24.6 | 6.79 ± 14.9 | 7.54 ± 11.8 |
| M2-TEZ: Day 1 | 0.553 ± 47.0 | 0.667 ± 39.6 | 0.716 ± 17.0 |
| M2-TEZ: Day 7 | 4.72 ± 30.3 | 6.41 ± 33.2 | 5.46 ± 29.4 |
| M2-TEZ: Day 14 | 7.69 ± 23.7 | 10.1 ± 24.2 | 7.93 ± 28.3 |
| microgram*hour per milliliter | Part C: VX-445/TEZ/IVA TC (Cohort C1) | Part C: VX-445/TEZ/IVA TC (Cohort C2) | Part C: VX-445/TEZ/IVA TC (Cohort C3) |
|---|---|---|---|
| VX-445: Day 1 | 48.6 ± 22.7 | 72.5 ± 20.7 | 26.4 ± 13.8 |
| VX-445: Day 7 | 156 ± 37.1 | 177 ± 30.0 | 65.4 ± 20.7 |
| VX-445: Day 14 | 345 ± 30.7 | 506 ± 31.5 | 183 ± 18.8 |
| TEZ: Day 1 | 41.4 ± 27.5 | 43.8 ± 9.91 | 42.7 ± 20.9 |
| TEZ: Day 7 | 103 ± 35.8 | 105 ± 16.5 | 96.9 ± 18.9 |
| TEZ: Day 14 | 252 ± 35.1 | 288 ± 13.6 | 275 ± 19.5 |
| M1-TEZ: Day 1 | 17.7 ± 37.2 | 20.1 ± 35.2 | 25.5 ± 19.1 |
| M1-TEZ: Day 7 | 90.9 ± 29.9 | 110 ± 17.8 | 125 ± 14.1 |
| M1-TEZ: Day 14 | 380 ± 22.1 | 477 ± 16.0 | 512 ± 17.9 |
| M2-TEZ: Day 1 | 6.65 ± 48.6 | 8.19 ± 52.5 | 9.00 ± 16.6 |
| M2-TEZ: Day 7 | 108 ± 31.2 | 143 ± 34.1 | 123 ± 28.7 |
| M2-TEZ: Day 14 | 617 ± 23.2 | 831 ± 29.5 | 652 ± 31.2 |
| nanogram per milliliter | Part C: VX-445/TEZ/IVA TC (Cohort C1) | Part C: VX-445/TEZ/IVA TC (Cohort C2) | Part C: VX-445/TEZ/IVA TC (Cohort C3) |
|---|---|---|---|
| IVA: Day 1 | 425 ± 29.8 | 461 ± 49.3 | 437 ± 9.63 |
| IVA: Day 7 | 1290 ± 41.1 | 1190 ± 42.4 | 1070 ± 20.0 |
| IVA: Day 14 | 1360 ± 21.9 | 1920 ± 33.7 | 1410 ± 25.5 |
| M1-IVA: Day 1 | 1250 ± 29.9 | 1190 ± 28.1 | 1070 ± 28.6 |
| M1-IVA: Day 7 | 2460 ± 26.8 | 2590 ± 28.1 | 2070 ± 23.1 |
| M1-IVA: Day 14 | 2680 ± 19.4 | 3900 ± 21.4 | 2990 ± 28.3 |
| M6-IVA: Day 1 | 901 ± 38.2 | 1180 ± 16.6 | 631 ± 31.1 |
| M6-IVA: Day 7 | 1960 ± 38.1 | 2590 ± 7.3 | 1400 ± 29.8 |
| M6-IVA: Day 14 | 2060 ± 30.1 | 3350 ± 17.4 | 1980 ± 34.7 |
| nanogram*hour per milliliter | Part C: VX-445/TEZ/IVA TC (Cohort C1) | Part C: VX-445/TEZ/IVA TC (Cohort C2) | Part C: VX-445/TEZ/IVA TC (Cohort C3) |
|---|---|---|---|
| IVA: Day 1 | 6350 ± 40.9 | 6210 ± 45.5 | 5480 ± 28.5 |
| IVA: Day 7 | 21600 ± 65.6 | 18800 ± 50.7 | 16900 ± 28.4 |
| IVA: Day 14 | 27900 ± 48.7 | 35000 ± 44.8 | 32600 ± 40.6 |
| M1-IVA: Day 1 | 16900 ± 38.9 | 14800 ± 32.3 | 13300 ± 21.1 |
| M1-IVA: Day 7 | 47500 ± 43.6 | 46300 ± 30.6 | 36400 ± 25.9 |
| M1-IVA: Day 14 | 75300 ± 42.7 | 97000 ± 31.3 | 86100 ± 30.2 |
| M6-IVA: Day 1 | 11100 ± 49.9 | 14100 ± 20.3 | 9050 ± 26.1 |
| M6-IVA: Day 7 | 39700 ± 38.8 | 51400 ± 13.0 | 29100 ± 36.0 |
| M6-IVA: Day 14 | 66300 ± 44.9 | 123000 ± 23.1 | 67100 ± 42.3 |
| microgram per milliliter | Part C: VX-445/TEZ/IVA TC (Cohort C1) | Part C: VX-445/TEZ/IVA TC (Cohort C2) | Part C: VX-445/TEZ/IVA TC (Cohort C3) |
|---|---|---|---|
| VX-445: Day 7 | 4.63 ± 46.8 | 5.91 ± 35.5 | 2.09 ± 14.9 |
| VX-445: Day 14 | 4.45 ± 38.9 | 7.60 ± 29.8 | 2.92 ± 13.2 |
| TEZ: Day 7 | 2.73 ± 48.7 | 2.77 ± 19.2 | 2.52 ± 23.0 |
| TEZ: Day 14 | 3.10 ± 33.4 | 3.70 ± 16.0 | 3.62 ± 24.6 |
| M1-TEZ: Day 7 | 3.36 ± 27.1 | 3.98 ± 16.8 | 4.71 ± 14.0 |
| M1-TEZ: Day 14 | 4.38 ± 20.5 | 5.42 ± 16.1 | 5.52 ± 12.9 |
| M2-TEZ: Day 7 | 4.06 ± 32.8 | 5.63 ± 37.5 | 4.92 ± 27.7 |
| M2-TEZ: Day 14 | 6.46 ± 22.5 | 8.85 ± 29.9 | 7.38 ± 29.6 |
| nanogram per milliliter | Part C: VX-445/TEZ/IVA TC (Cohort C1) | Part C: VX-445/TEZ/IVA TC (Cohort C2) | Part C: VX-445/TEZ/IVA TC (Cohort C3) |
|---|---|---|---|
| IVA: Day 7 | 753 ± 75 | 759 ± 45.7 | 604 ± 32.8 |
| IVA: Day 14 | 610 ± 55.6 | 990 ± 43.4 | 881 ± 35.3 |
| M1-IVA: Day 7 | 1790 ± 43.7 | 1960 ± 21.4 | 1400 ± 21.3 |
| M1-IVA: Day 14 | 1600 ± 46.2 | 2210 ± 19.8 | 1930 ± 16.9 |
| M6-IVA: Day 7 | 1530 ± 31.5 | 2260 ± 11.9 | 1270 ± 32.1 |
| M6-IVA: Day 14 | 1360 ± 49.1 | 2600 ± 18.0 | 1640 ± 27.0 |
| microgram per milliliter | Part D: VX-445/TEZ/IVA TC - Low Dose | Part D: VX-445/TEZ/IVA TC - Medium Dose | Part D: VX-445/TEZ/IVA TC - High Dose |
|---|---|---|---|
| VX-445: Day 15 | 1.04 ± 0.612 | 2.15 ± 0.977 | 5.77 ± 4.14 |
| VX-445: Day 29 | 1.27 ± 0.530 | 2.18 ± 1.26 | 5.57 ± 2.80 |
| TEZ: Day 15 | 1.85 ± 1.26 | 1.68 ± 0.700 | 1.76 ± 0.960 |
| TEZ: Day 29 | 2.16 ± 1.27 | 1.77 ± 0.833 | 2.22 ± 1.62 |
| M1-TEZ: Day 15 | 4.46 ± 1.96 | 4.11 ± 1.47 | 4.43 ± 1.79 |
| M1-TEZ: Day 29 | 4.77 ± 2.04 | 4.30 ± 1.55 | 4.74 ± 1.89 |
| IVA: Day 15 | 0.720 ± 0.484 | 0.665 ± 0.414 | 0.701 ± 0.593 |
| IVA: Day 29 | 0.753 ± 0.424 | 0.704 ± 0.414 | 0.658 ± 0.386 |
| M1-IVA: Day 15 | 1.29 ± 0.748 | 1.21 ± 0.666 | 1.45 ± 1.22 |
| M1-IVA: Day 29 | 1.57 ± 0.830 | 1.20 ± 0.717 | 1.29 ± 0.797 |
| microgram per milliliter | Part E: TEZ/IVA | Part E: VX-445/TEZ/IVA TC |
|---|---|---|
| VX-445: Day 15 | — | 5.07 ± 2.47 |
| VX-445: Day 29 | — | 5.35 ± 3.73 |
| TEZ: Day 15 | 1.85 ± 0.863 | 1.86 ± 1.09 |
| TEZ: Day 29 | 1.84 ± 1.28 | 1.99 ± 1.55 |
| M1-TEZ: Day 15 | 3.96 ± 1.76 | 4.57 ± 1.73 |
| M1-TEZ: Day 29 | 3.73 ± 1.51 | 4.71 ± 1.86 |
| IVA: Day 15 | 0.766 ± 0.366 | 0.659 ± 0.529 |
| IVA: Day 29 | 0.595 ± 0.303 | 0.798 ± 0.901 |
| M1-IVA: Day 15 | 1.22 ± 0.470 | 1.09 ± 0.973 |
| M1-IVA: Day 29 | 0.943 ± 0.431 | 1.43 ± 1.54 |
| microgram per milliliter | Part F: VX-445/TEZ/VX-561 TC |
|---|---|
| VX-445: Day 15 | 4.40 ± 1.54 |
| VX-445: Day 29 | 5.25 ± 2.88 |
| TEZ: Day 15 | 1.80 ± 0.658 |
| TEZ: Day 29 | 2.22 ± 1.65 |
| M1-TEZ: Day 15 | 4.99 ± 1.71 |
| M1-TEZ: Day 29 | 5.09 ± 1.37 |
| VX-561: Day 15 | 0.441 ± 0.174 |
| VX-561: Day 29 | 0.597 ± 0.473 |
Sweat samples were collected using an approved collection device.
| millimole per liter (mmol/L) | Part D: Placebo | Part D: VX-445/TEZ/IVA TC - Low Dose | Part D: VX-445/TEZ/IVA TC - Medium Dose | Part D: VX-445/TEZ/IVA TC - High Dose |
|---|---|---|---|---|
| Part D: Absolute Change in Sweat Chloride Concentration | -2.2 ± 3.9 | -38.2 ± 4.2 | -33.2 ± 2.8 | -39.1 ± 2.9 |
Sweat samples were collected using an approved collection device.
| mmol/L | Part E: TEZ/IVA | Part E: VX-445/TEZ/IVA TC |
|---|---|---|
| Part E: Absolute Change in Sweat Chloride Concentration | 0.8 ± 4.9 | -39.6 ± 2.8 |
Sweat samples were collected using an approved collection device.
| mmol/L | Part F: Placebo | Part F: VX-445/TEZ/VX-561 TC |
|---|---|---|
| Part F: Absolute Change in Sweat Chloride Concentration | 1.0 ± 4.6 | -33.6 ± 2.8 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percent change | Part D: Placebo | Part D: VX-445/TEZ/IVA TC - Low Dose | Part D: VX-445/TEZ/IVA TC - Medium Dose | Part D: VX-445/TEZ/IVA TC - High Dose |
|---|---|---|---|---|
| Part D: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) | 0.3 ± 4.0 | 19.3 ± 4.2 | 13.8 ± 2.8 | 26.2 ± 2.9 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percent change | Part E: TEZ/IVA | Part E: VX-445/TEZ/IVA TC |
|---|---|---|
| Part E: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) | 1.4 ± 5.0 | 19.2 ± 2.7 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percent change | Part F: Placebo | Part F: VX-445/TEZ/VX-561 TC |
|---|---|---|
| Part F: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) | 1.6 ± 4.6 | 19.9 ± 2.8 |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| units on a scale | Part D: Placebo | Part D: VX-445/TEZ/IVA TC - Low Dose | Part D: VX-445/TEZ/IVA TC - Medium Dose | Part D: VX-445/TEZ/IVA TC - High Dose |
|---|---|---|---|---|
| Part D: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score | 4.2 ± 4.9 | 20.8 ± 5.4 | 15.4 ± 3.7 | 25.7 ± 3.7 |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| units on a scale | Part E: TEZ/IVA | Part E: VX-445/TEZ/IVA TC |
|---|---|---|
| Part E: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score | 5.2 ± 7.1 | 20.7 ± 4.0 |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| units on a scale | Part F: Placebo | Part F: VX-445/TEZ/VX-561 TC |
|---|---|---|
| Part F: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score | 20.2 ± 6.9 | 20.2 ± 4.3 |
Collected over Parts A, B and C: From first dose of study drug in treatment period up to safety follow-up (up to 28 days); Parts D, E and F: From first dose of study drug in TC treatment period up to 28 days after last dose of study drug (up to 5 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Pooled Placebo (Except Cohort A7) | 0/9 (0%) | 0/9 (0%) | 0/9 (0%) |
| Part A: VX-445 (Except Cohort A7) | 0/30 (0%) | 0/30 (0%) | 3/30 (10%) |
| Part A: VX-445 (Cohort A7) | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Part B: Pooled Placebo (Cohort B1 to B4) | 0/7 (0%) | 0/7 (0%) | 2/7 (28.6%) |
| Part B: VX-445 (Cohort B1 to B4) | 0/25 (0%) | 0/25 (0%) | 2/25 (8%) |
| Part C: Pooled Placebo (Cohort C1 to C3) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3) | 0/17 (0%) | 0/17 (0%) | 5/17 (29.4%) |
| Part D: Placebo | 0/12 (0%) | 2/12 (16.7%) | 12/12 (100%) |
| Part D: VX-445/TEZ/IVA TC - Low Dose | 0/10 (0%) | 1/10 (10%) | 10/10 (100%) |
| Part D: VX-445/TEZ/IVA TC - Medium Dose | 0/22 (0%) | 2/22 (9.1%) | 19/22 (86.4%) |
| Part D: VX-445/TEZ/IVA TC - High Dose | 0/21 (0%) | 0/21 (0%) | 17/21 (81%) |
| Part E: TEZ/IVA | 0/7 (0%) | 1/7 (14.3%) | 5/7 (71.4%) |
| Part E: VX-445/TEZ/IVA TC | 0/21 (0%) | 0/21 (0%) | 18/21 (85.7%) |
| Part F: Placebo | 0/8 (0%) | 1/8 (12.5%) | 7/8 (87.5%) |
| Part F: VX-445/TEZ/VX-561 TC | 0/21 (0%) | 0/21 (0%) | 17/21 (81%) |
| Event | Part A: Pooled Placebo (Except Cohort A7) | Part A: VX-445 (Except Cohort A7) | Part A: VX-445 (Cohort A7) | Part B: Pooled Placebo (Cohort B1 to B4) | Part B: VX-445 (Cohort B1 to B4) | Part C: Pooled Placebo (Cohort C1 to C3) | Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3) | Part D: Placebo | Part D: VX-445/TEZ/IVA TC - Low Dose | Part D: VX-445/TEZ/IVA TC - Medium Dose | Part D: VX-445/TEZ/IVA TC - High Dose | Part E: TEZ/IVA | Part E: VX-445/TEZ/IVA TC | Part F: Placebo | Part F: VX-445/TEZ/VX-561 TC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 0/9 | 0/30 | 0/8 | 0/7 | 0/25 | 0/6 | 0/17 | 1/12 | 1/10 | 2/22 | 0/21 | 1/7 | 0/21 | 1/8 | 0/21 |
| Distal intestinal obstruction syndromeGastrointestinal disorders | 0/9 | 0/30 | 0/8 | 0/7 | 0/25 | 0/6 | 0/17 | 0/12 | 1/10 | 0/22 | 0/21 | 0/7 | 0/21 | 0/8 | 0/21 |
| Jugular vein thrombosisRespiratory, thoracic and mediastinal disorders | 0/9 | 0/30 | 0/8 | 0/7 | 0/25 | 0/6 | 0/17 | 0/12 | 1/10 | 0/22 | 0/21 | 0/7 | 0/21 | 0/8 | 0/21 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/9 | 0/30 | 0/8 | 0/7 | 0/25 | 0/6 | 0/17 | 1/12 | 0/10 | 0/22 | 0/21 | 0/7 | 0/21 | 0/8 | 0/21 |
| Influenza A virus test positiveInvestigations | 0/9 | 0/30 | 0/8 | 0/7 | 0/25 | 0/6 | 0/17 | 0/12 | 0/10 | 1/22 | 0/21 | 0/7 | 0/21 | 0/8 | 0/21 |
| Event | Part A: Pooled Placebo (Except Cohort A7) | Part A: VX-445 (Except Cohort A7) | Part A: VX-445 (Cohort A7) | Part B: Pooled Placebo (Cohort B1 to B4) | Part B: VX-445 (Cohort B1 to B4) | Part C: Pooled Placebo (Cohort C1 to C3) | Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3) | Part D: Placebo | Part D: VX-445/TEZ/IVA TC - Low Dose | Part D: VX-445/TEZ/IVA TC - Medium Dose | Part D: VX-445/TEZ/IVA TC - High Dose | Part E: TEZ/IVA | Part E: VX-445/TEZ/IVA TC | Part F: Placebo | Part F: VX-445/TEZ/VX-561 TC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 0/9 | 0/30 | 0/8 | 0/7 | 0/25 | 0/6 | 1/17 | 1/12 | 4/10 | 5/22 | 7/21 | 1/7 | 7/21 | 2/8 | 5/21 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 0/9 | 0/30 | 0/8 | 0/7 | 0/25 | 0/6 | 0/17 | 3/12 | 3/10 | 4/22 | 5/21 | 0/7 | 8/21 | 1/8 | 3/21 |
| NauseaGastrointestinal disorders | 0/9 | 1/30 | 0/8 | 0/7 | 0/25 | 1/6 | 0/17 | 2/12 | 2/10 | 3/22 | 1/21 | 1/7 | 1/21 | 3/8 | 2/21 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 0/9 | 0/30 | 0/8 | 0/7 | 0/25 | 0/6 | 0/17 | 4/12 | 2/10 | 4/22 | 2/21 | 0/7 | 5/21 | 3/8 | 3/21 |
| FatigueGeneral disorders | 0/9 | 0/30 | 0/8 | 0/7 | 0/25 | 0/6 | 1/17 | 4/12 | 1/10 | 0/22 | 0/21 | 0/7 | 4/21 | 0/8 | 0/21 |
| VomitingGastrointestinal disorders | 0/9 | 0/30 | 0/8 | 0/7 | 0/25 | 0/6 | 1/17 | 0/12 | 0/10 | 1/22 | 1/21 | 1/7 | 0/21 | 2/8 | 0/21 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/9 | 0/30 | 0/8 | 0/7 | 0/25 | 0/6 | 0/17 | 2/12 | 2/10 | 2/22 | 2/21 | 1/7 | 1/21 | 2/8 | 5/21 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/9 | 0/30 | 0/8 | 0/7 | 0/25 | 0/6 | 0/17 | 2/12 | 0/10 | 5/22 | 2/21 | 0/7 | 3/21 | 1/8 | 1/21 |
| PyrexiaGeneral disorders | 0/9 | 0/30 | 0/8 | 0/7 | 0/25 | 0/6 | 0/17 | 1/12 | 0/10 | 5/22 | 1/21 | 1/7 | 3/21 | 0/8 | 0/21 |
| HeadacheNervous system disorders | 0/9 | 0/30 | 0/8 | 0/7 | 1/25 | 0/6 | 2/17 | 2/12 | 2/10 | 2/22 | 2/21 | 1/7 | 0/21 | 1/8 | 1/21 |
| Age, Categorical(Participants) | Part A: Pooled Placebo (Except Cohort A7) | Part A: VX-445 (Except Cohort A7) | Part A: VX-445 (Cohort A7) | Part B: Pooled Placebo (Cohort B1 to B4) | Part B: VX-445 (Cohort B1 to B4) | Part C: Pooled Placebo (Cohort C1 to C3) | Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3) | Part D: Placebo | Part D: VX-445/TEZ/IVA TC - Low Dose | Part D: VX-445/TEZ/IVA TC - Medium Dose | Part D: VX-445/TEZ/IVA TC - High Dose | Part E: TEZ/IVA | Part E: VX-445/TEZ/IVA TC | Part F: Placebo | Part F: VX-445/TEZ/VX-561 TC | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 9 | 30 | 8 | 7 | 25 | 6 | 17 | 12 | 10 | 22 | 21 | 7 | 21 | 8 | 21 | 224 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Part A: Pooled Placebo (Except Cohort A7) | Part A: VX-445 (Except Cohort A7) | Part A: VX-445 (Cohort A7) | Part B: Pooled Placebo (Cohort B1 to B4) | Part B: VX-445 (Cohort B1 to B4) | Part C: Pooled Placebo (Cohort C1 to C3) | Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3) | Part D: Placebo | Part D: VX-445/TEZ/IVA TC - Low Dose | Part D: VX-445/TEZ/IVA TC - Medium Dose | Part D: VX-445/TEZ/IVA TC - High Dose | Part E: TEZ/IVA | Part E: VX-445/TEZ/IVA TC | Part F: Placebo | Part F: VX-445/TEZ/VX-561 TC | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 2 | 0 | 0 | 3 | 0 | 0 | 2 | 6 | 7 | 11 | 1 | 9 | 5 | 10 | 58 |
| Male | 7 | 28 | 8 | 7 | 22 | 6 | 17 | 10 | 4 | 15 | 10 | 6 | 12 | 3 | 11 | 166 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Pooled Placebo (Except Cohort A7) | Part A: VX-445 (Except Cohort A7) | Part A: VX-445 (Cohort A7) | Part B: Pooled Placebo (Cohort B1 to B4) | Part B: VX-445 (Cohort B1 to B4) | Part C: Pooled Placebo (Cohort C1 to C3) | Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3) | Part D: Placebo | Part D: VX-445/TEZ/IVA TC - Low Dose | Part D: VX-445/TEZ/IVA TC - Medium Dose | Part D: VX-445/TEZ/IVA TC - High Dose | Part E: TEZ/IVA | Part E: VX-445/TEZ/IVA TC | Part F: Placebo | Part F: VX-445/TEZ/VX-561 TC | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 | 0 | 1 | 1 | 5 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 13 |
| Not Hispanic or Latino | 9 | 28 | 6 | 7 | 24 | 5 | 12 | 12 | 10 | 22 | 20 | 7 | 20 | 8 | 20 | 210 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Part A: Pooled Placebo (Except Cohort A7) | Part A: VX-445 (Except Cohort A7) | Part A: VX-445 (Cohort A7) | Part B: Pooled Placebo (Cohort B1 to B4) | Part B: VX-445 (Cohort B1 to B4) | Part C: Pooled Placebo (Cohort C1 to C3) | Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3) | Part D: Placebo | Part D: VX-445/TEZ/IVA TC - Low Dose | Part D: VX-445/TEZ/IVA TC - Medium Dose | Part D: VX-445/TEZ/IVA TC - High Dose | Part E: TEZ/IVA | Part E: VX-445/TEZ/IVA TC | Part F: Placebo | Part F: VX-445/TEZ/VX-561 TC | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 16 | 4 | 3 | 9 | 4 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 42 |
| White | 5 | 14 | 4 | 2 | 16 | 2 | 16 | 12 | 8 | 22 | 21 | 7 | 21 | 8 | 20 | 178 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2017 to primary completion in Mar 2018, 14 months.
Results were first posted in Jan 2022, 3 years 9 months after primary completion. A results delay was requested in Mar 2019.
Of 26 phase 1/2 interventional studies under Cystic Fibrosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's 14 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tezacaftor · Ivacaftor · Elexacaftor
Vertex Pharmaceuticals Incorporated →